New results from a closely watched clinical trial showed that weight-loss drugs are effective for children as young as 6, though some doctors say they are concerned about the prospect of prescribing these medications to such young patients.
The study, presented Monday at the medical conference Obesity Week, examined children ages 6 to 11 who were taking semaglutide, the compound in Ozempic and Wegovy. Most children in the trial had severe obesity, meaning they had a body mass index of 35 or higher. After 68 weeks, nearly 40 percent of those who took the drug no longer had obesity, compared with none of the patients on a placebo.
Novo Nordisk, the drug’s maker, said it would ask the Food and Drug Administration to approve the medication for this age group. The drug is already authorized for children 12 and over. Another new study, also presented at the conference, showed that the weight-loss drug tirzepatide was effective in children age 12 and older.
Doctors widely agree that more needs to be done to address obesity, which affects roughly one in five children and adolescents nationwide. But they are divided over whether powerful GLP-1 drugs, which rewire the brain’s relationship to food, are the right approach. Some are concerned about the potential long-term implications of putting children who are still growing on a drug that erases appetite and can lead people to consume very few calories.
In October, the World Health Organization cautioned against using weight-loss drugs in children under 10, citing a lack of evidence on their effects on children’s growth, development and mental health.
“The question is: Is this the right thing to do?” said Dr. Robert Lustig, a professor of pediatrics at the University of California, San Francisco. “Not, does it work? Of course it works. But is it the right thing?”
Use of these medications among children is rare, but rising: A recent paper found that around 20,000 children ages 8 to 11 were prescribed weight-loss drugs from 2019 to 2026, with annual prescriptions rising significantly over that time period.
Physicians who prescribe these drugs to young children say they want to address obesity as early as possible, to prevent children from developing severe obesity or related health conditions, including diabetes, liver disease and high blood pressure.
“‘Let’s just wait and close our eyes until they turn 18 before we deal with it’ is not a great option,” said Dr. Sarah Barlow, a pediatric gastroenterologist at UT Southwestern Medical Center and Children’s Health.
Some doctors think that improving a child’s diet and promoting exercise should be the first line of treatment. Others say that these changes are not aggressive enough to combat severe obesity. A mounting body of research suggests that obesity is at least partly the result of a person’s underlying biology and genetics.
“There are kids who, just like adults, can do everything, but it’s not enough,” said Dr. Pamela Hu, an assistant professor of pediatrics at the Yale School of Medicine.
The study on semaglutide for young children followed 167 children for around two years. All of them received counseling about nutrition and physical activity. Those who took the medication saw their body mass indexes fall by an average of around 9 percentage points during that time, while those in the placebo group had their B.M.I.s rise by an average of 8 percentage points.
Separately, the new study on tirzepatide, which included 160 adolescents with obesity, reported that those who took the medication experienced an around 18 percent reduction in body mass index, on average, after 72 weeks. In both trials, the most common side effects were gastrointestinal issues, like vomiting, nausea, and diarrhea.
There are a number of unanswered questions about how the medications might affect children’s development, including whether nutritional deficiencies could affect their growth or the process of puberty. Some doctors also worry that the drugs could trigger or mask eating disorders in children and teens.
It can be risky “if more weight loss, in one’s mind, is always better,” Dr. Barlow said.
There is also a risk of muscle loss on these medications. The standard advice for patients to consume plenty of protein and strength train to preserve their muscle may be more challenging to encourage in children, doctors said.
Perhaps the biggest question is whether children need to remain on a weight-loss drug permanently — and what happens if they do. There is not yet decades of data on these drugs, but short-term studies show adults who stop the medications typically regain weight and lose other benefits, like protection against cardiovascular disease.
Trials will continue to follow children on these drugs. But for now, parents and providers have only a limited understanding of whether the potential risks outweigh the benefits.
Dr. Susan Woolford, director of the Michigan Intensive Pediatric Lifestyle and Navigation weight management clinic, said that if prescribing the drugs to young children becomes common practice, it will be a paradigm shift. For decades, doctors have had few options to address childhood obesity.
Now, she said, “We’re given a power tool.”
